Compare · NVO vs TYRA
NVO vs TYRA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tyra Biosciences Inc. (TYRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TYRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 82.2x TYRA ($2.24B).
- Over the past year, NVO is down 34.2% and TYRA is up 263.8% - TYRA leads by 298.1 points.
- TYRA has been more active in the news (10 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for TYRA).
- Company
- Novo Nordisk A/S
- Tyra Biosciences Inc.
- Price
- $41.18+6.93%
- $37.62+2.51%
- Market cap
- $183.82B
- $2.24B
- 1M return
- +13.32%
- +2.34%
- 1Y return
- -34.24%
- +263.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 10
- Recent ratings
- 25
- 20
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Tyra Biosciences Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest TYRA
- Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.
- SEC Form 4 filed by Dable Habib J
- SEC Form 3 filed by new insider Dable Habib J
- SEC Form DEFA14A filed by Tyra Biosciences Inc.
- SEC Form DEF 14A filed by Tyra Biosciences Inc.
- SEC Form 8-K filed by Tyra Biosciences Inc.
- Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
- Guggenheim initiated coverage on Tyra Biosciences with a new price target
- SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.
- Canaccord Genuity initiated coverage on Tyra Biosciences with a new price target